*P. vivax* was detected by PCR in 45% of children aged 5-10 years from our study area in Papua New Guinea (PNG). 504 children were randomized into 2 arms according to Primaquine (PQ) treatment or not at baseline and actively and passively followed for 9 months. We genotyped all *P. vivax* infections, the majority of these being multi-clone infections. All blood samples positive for *P. vivax* by qPCR were tested for gametocyte carriage by targeting *pvs25* transcripts. Primaquine reduced the risk of *P. vivax* infections by 80%. The multiplicity of infection and the density of asexual *P. vivax* stages were not significantly different in both treatment arms. The number of new clones (force of blood-stage infection) was 2.38 ± 0.17 per person per year-at-risk in the PQ-arm compared to 8.04 ± 0.41 in the Placebo arm (*P* \< 0.05). The duration of infections did not differ between the treatment arms, with 73 days \[95% CI: 33-849\] and 68 days \[95% CI: 40-247\] in the PQ or Placebo arm, respectively. Detectability of *P. vivax* clones was low with 0.26 ± 0.06 and 0.24 ± 0.04 in the PQ and Placebo arms. PQ-treated children had a 75% lower risk of carrying gametocytes compared to Placebo recipients. *P. vivax* positive children in both arms were equally likely to show gametocyte positivity. We conclude that *P. vivax* relapses contribute significantly to the high burden of *P. vivax* infection and transmission in PNG. All other infection dynamics parameters were consistent between treatment arms and apparent relapses behave like new infections.
